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ABSTRACT
Carbapenem resistance associated with class D
b-lactamases is an increasing problem in Acineto-
bacter baumannii. Most enzymes of this class
reported so far belong to two subgroups, 1 and 2;
however, a novel class D carbapenemase (OXA-51)
has been reported recently which shares 56% and
< 63% amino-acid identity with subgroups 1 and
2, respectively, and which belongs to a third
subgroup. This study describes a further seven
novel subgroup 3 b-lactamases in carbapenem-
resistant A. baumannii isolates from four conti-
nents.
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Acinetobacter baumannii is an opportunistic
nosocomial pathogen associated with a range of
infections, particularly in ventilated patients in
intensive therapy units [1,2]. An alarming trend
has been the emergence of multiresistant isolates
that are resistant to one or more of the carbapen-
ems, with the result that pan-drug resistance is
now emerging [3]. b-Lactamase-mediated carb-
apenem resistance is being reported with increas-
ing frequency. Some isolates from Asia, southern
Europe and the UK have IMP and VIM molecular
class B metallo-b-lactamases [4–7], but carbape-
nem-hydrolysing b-lactamases that belong to
class D have also been described. The ﬁrst class
D carbapenemase (OXA-23) [8] was detected in an
imipenem-resistant isolate from Edinburgh in
1985 [9] that belongs to subgroup 1, along with
OXA-27 (Singapore) [10] and OXA-49 (China)
(GenBank accession number AY288523). OXA-24,
-25, -26 and -40, identiﬁed in isolates from Spain,
Belgium, France and Portugal, differ by one or
two amino-acids, and belong to subgroup 2
[10–13]. The two subgroups share 60% amino-
acid homology, but all of these enzymes possess a
tyrosine-to-phenylalanine substitution in the con-
served Y-G-N motif of the class D protein [14]. A
novel class D carbapenemase (OXA-51) has been
characterised recently in two distinct clones of
A. baumannii from Argentina. OXA-51 shares 56%
and 61–62% amino-acid homology with sub-
groups 1 and 2, respectively, and thus represents
a new subgroup of carbapenemases in Acinetob-
acter [15]. The present report describes a further
seven novel class D b-lactamases belonging to this
new subgroup in carbapenem-resistant A. bau-
mannii isolates collected worldwide.
Multiresistant A. baumannii clinical isolates
were collected between 1996 and 2000 from
centres in Argentina, South Africa, Hong Kong,
Spain, Singapore and Turkey. Ten isolates from
Argentina included in this study belonged to two
clones (designated as pulsed-ﬁeld gel electro-
phoresis genotypes B and C) that were identiﬁed
previously in an outbreak of carbapenem resistant
isolates from two hospitals in Buenos Aires (39th
Interscience Conference on Antimicrobial Agents
and Chemotherapy, abstract 1463); clones B and C
were distinct from two other clones of carbape-
nem-resistant A. baumannii that produced the
OXA-51 carbapenemase [15]. The isolates from
Turkey included six related multiresistant
A. baumannii isolates (designated as pulsed-ﬁeld
gel electrophoresis genotype D) that were collec-
ted from the surgical intensive care unit of Dokuz
Eylul University Hospital in Izmir (39th Inter-
science Conference on Antimicrobial Agents and
Chemotherapy, abstract 1463). The remaining
isolates in this study included two from South
Africa collected from the Chris Hani Baragwanath
Hospital, Soweto, three isolates from the KK
Women’s and Children’s Hospital, Singapore,
two isolates from a hospital clinic in Barcelona,
and two isolates from the Prince of Wales Hos-
pital, Hong Kong. Clinical A. baumannii strains
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789 (carbapenem-susceptible) and 788 (OXA-51
producer) were included as controls for PCR
analysis.
Imipenem and meropenem MICs were deter-
mined according to published guidelines [16,17].
DNA was extracted from isolates for PCR analysis
by boiling one to three colonies in 100 lL of sterile
ultra-pure water for 10 min and centrifuging
brieﬂy. PCRs (50-lL ﬁnal volumes) contained
2 lL of DNA extract, 20 mM Tris-HCl (pH 8.8),
10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4,
0.8 mM dNTPs and 1.25 U of Pfu DNA polym-
erase (Promega, Southampton, UK). To determine
the presence of blaOXA-51-related sequences,
primers designed to amplify the OXA-51 gene
[15] were used. PCR conditions on a Techne Px2
Gradient Thermal Cycler (Thermo Hybaid,
Ashford, UK) comprised 95C for 5 min, followed
by 30 cycles of 95C for 1 min, 50C for 1 min and
72C for 2 min, with a ﬁnal extension period of
72C for 10 min. Puriﬁed amplicons from three
separate PCRs were sequenced in both directions
on an ABI Prism Automated Sequencer (Perkin-
Elmer, Beaconsﬁeld, UK). Protein sequences were
aligned by hierarchical clustering [18].
The isolates studied had imipenem and
meropenem MICs of 4–128 mg ⁄L, suggesting that
additional factors, such as outer-membrane imper-
meability, may also be involved in the carbapenem
resistance of these isolates. Sequencing of an
ampliﬁed 1000-bp product identiﬁed a gene with
an 825-bp open reading frame that encoded a
protein with 274 amino-acids. Analysis of the
protein from Argentinian strains 884 (clone B) and
790 (clone C) identiﬁed a novel b-lactamase (des-
ignated OXA-65) that shared 98% amino-acid
identity with OXA-51. A further six novel
sequences with 97–98% amino-acid homology
with OXA-51 (Fig. 1) were identiﬁed, namely
OXA-64 in isolate 889 (South Africa), OXA-66
in isolates 806 (Spain), 811 (Hong Kong) and
864 (Singapore), OXA-68 in isolate 809 (Spain),
OXA-69 in isolates 877, 881 (both Singapore) and
823 (clone D, Turkey), OXA-70 in isolate 812 (Hong
Kong), and OXA-71 in isolate 888 (South Africa).
Comparison of these enzymes with OXA-51
identiﬁed between three and eight amino-acid
substitutions (Table 1). All had an A ﬁ G change
at nucleotide position 13, resulting in a threonine-
to-alanine substitution at amino-acid 5. In addi-
tion, blaOXA-71 had an A ﬁ C change at the third
position in this codon (Table 1). Each of these
OXA-65
OXA-66
OXA-69
OXA-64
OXA-71
OXA-51
OXA-70
OXA-68
OXA-26
OXA-40
OXA-24
OXA-25
OXA-23
OXA-49
OXA-27
Subgroup 3
Subgroup 2
Subgroup 1
0.5
Fig. 1. Relationship of subgroup 3 to other OXA-type
carbapenemases found in Acinetobacter spp. Analysis was
performed with BioNumerics v. 2.5 (Applied Maths BVBA,
Sint-Martens-Latem, Belgium). A gap penalty of 3 was
applied.
Table 1. Amino-acid changes detected in subgroup 3
carbapenemases related to OXA-51
Amino-acid position
(related to OXA-51) Amino-acid changea OXA
5 Thr ﬁ Ala
(ACA) ﬁ (GCA) ) 64, ) 65, ) 66, ) 68, ) 69, ) 70, ) 71
(ACA) ﬁ (GCC) ) 71
24 Thr ﬁ Ser
(ACT) ﬁ (TCT) ) 68
36 Glu ﬁ Asp
(GAA) ﬁ (GAC) ) 69
36 Glu ﬁ Lys
(GAA) ﬁ (AAA) ) 70
36 Glu ﬁ Val
(GAA) ﬁ (GTA) ) 66
38 Ala ﬁ Gly
(GCA) ﬁ (GGA) ) 64
48 Val ﬁ Ala
(GTA) ﬁ (GCA) ) 64, ) 65, ) 66, ) 68, ) 69, ) 70, 71
57 Gln ﬁ His
(CAA) ﬁ (CAT) ) 69
96 Ala ﬁ Thr
(GCA) ﬁ (ACA) ) 71
105 Asp ﬁ Asn
(GAC) ﬁ (AAC) ) 70
107 Gln ﬁ Lys
(CAA) ﬁ (AAA) ) 65, ) 66
107 Gln ﬁ Glu
(CAA) ﬁ (GAA) ) 69
117 Asp ﬁ Asn
(GAC) ﬁ (AAC) ) 68, ) 69
146 Lys ﬁ Asn
(AAG) ﬁ (AAT) ) 68, ) 70
194 Pro ﬁ Gln
(CCA) ﬁ (CAA) ) 65, ) 66, ) 68, ) 69, ) 70
195 Lys ﬁ Glu
(AAA) ﬁ (GAA) ) 68
198 Asp ﬁ His
(GAT) ﬁ (CAT) ) 70
225 Asp ﬁ Asn
(GAC) ﬁ (AAC) ) 65, ) 66, ) 68, 69
aCodons are in parentheses. Nucleotide changes are in bold.
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genes also had a T ﬁ C change at nucleotide
postion 143, causing a valine-to-alanine substitu-
tion at amino-acid 48. As observed with OXA-51,
all enzymes had a valine-to-isoleucine substitution
in the S-X-V class D motif (amino-acids 127–129 in
OXA-51) and, in contrast to carbapenemases in
subgroups 1 and 2 [8,10–12], a tyrosine of the Y-G-
N motif (amino-acids 153–155) was also retained
(data not shown). However, subgroup 3 enzymes
were similar to those in subgroup 2 in that the
K-T-Gmotif (amino-acids 217–219 in OXA-51) was
replaced by K-S-G [10–12]. Identical silent changes
were present at 11 nucleotide positions in at least
two different OXA genes (data not shown).
In conclusion, this study identiﬁed seven novel
OXA-type b-lactamases related to OXA-51 in
carbapenem-resistant A. baumannii isolates from
six countries, with two of these enzymes found in
isolates from more than one continent. Carba-
penemases in subgroup 2 have been identiﬁed so
far only in strains from Europe [10–13,19], and
OXA-23 is the only enzyme in subgroup 1 to have
been found in more than one country (GenBank
accession number AY288523) [20,21]. Conse-
quently, subgroup 3 now represents the largest
and most diverse collection of class D carbapene-
mases in A. baumannii, and may become the major
mechanism of carbapenem resistance in this
species.
NUCLEOTIDE SEQUENCE
ACCESSION NUMBERS
The sequence data reported in this study are
deposited in the GenBank nucleotide database
under accession numbers AY750907 (OXA-64),
AY750908 (OXA-65), AY750909 (OXA-66),
AY750910 (OXA-68), AY750911 (OXA-69),
AY750912 (OXA-70) and AY750913 (OXA-71).
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ABSTRACT
In total, 226 individuals from the community
were investigated for faecal carriage of Acinetob-
acter spp. by broth enrichment culture, followed
by growth on blood agar and ⁄ or Leeds Acinetob-
acter Medium (LAM). Acinetobacter baumannii was
isolated on both LAM and blood agar from one of
100 specimens in the UK and one of 126 speci-
mens in The Netherlands. The predominant
species were Acinetobactor johnsonii and genomic
sp. 11, which were cultured from 22 and ﬁve
specimens, respectively. A. baumannii did not
seem to be widespread in the faecal ﬂora of
individuals in the community.
Keywords Acinetobacter baumannii, Acinetobacter spp.,
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Acinetobacter baumannii is an increasingly import-
ant nosocomial pathogen which can cause major
outbreaks of infection. The organism is often
acquired nosocomially, but can be introduced
initially by patients admitted from other hospitals
[1]. Certain strains (clones) have been shown to be
distributed between hospitals in wide geograph-
ical areas [2–4]. However, the origin of a suddenly
appearing epidemic A. baumannii strain in a
hospital is often unknown, and it remains poss-
ible that A. baumannii has a reservoir in the non-
hospitalised human population, from which
strains can be introduced into a hospital. The
present study investigated the occurrence of
A. baumannii in faecal specimens from non-hos-
pitalised individuals in order to determine whe-
ther there is a signiﬁcant intestinal reservoir from
which spread to hospitals could occur. The study
was performed in Nottingham (UK) and Leiden
(The Netherlands), thus allowing comparison of
populations at two locations. In Nottingham, the
investigation focused exclusively on A. baumannii,
while in Leiden, the prevalence of other Acinetob-
acter spp. was also investigated.
In total, 226 individuals from the community
were investigated. One faecal specimen from each
individual was received from general practition-
ers for investigation of parasites or microbial
pathogens by the diagnostic laboratories at
Leiden University Medical Center and University
Hospital, Nottingham. A sterile cotton swab was
used to sample the faeces, and the material taken
up on the swab was transferred to ﬂasks contain-
ing 20 mL of acetate mineral medium [5]. The
samples were mixed to resuspend the faecal
material, and then incubated with vigorous aer-
ation for up to 48 h at 30C to enrich for
Acinetobacter spp. Following incubation, the cul-
tures were streaked on to Leeds Acinetobacter
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